AUS
NZ
UK
CA
USA
IND
Johnson & Johnson, the diversified healthcare leader based in New Brunswick, New Jersey, revealed its sales and earnings performance for the second quarter ending June 28, 2026, in a statement dated July 15, 2026. Signed by Controller and Principal Accounting Officer Robert J. Decker, Jr., the disclosure includes both quarterly and six-month comparative financial information. It also references unaudited supplementary sales data and a condensed consolidated earnings statement for the fiscal second quarter and six-month period. Johnson & Johnson’s common stock is traded on the New York Stock Exchange under the ticker symbol JNJ.
Key Highlights
- NYSE: JNJ (Johnson & Johnson’s common stock ticker symbol)
- Press release issued on July 15, 2026, covering sales and earnings for Q2 ended June 28, 2026
- Includes unaudited comparative supplementary sales data and condensed consolidated earnings statements for both Q2 and the six-month period
- Ten series of notes listed on the NYSE with maturities spanning November 2028 to February 2055, detailed in the filing
Johnson & Johnson Reports Financial Results for Second Quarter 2026
On July 15, 2026, Johnson & Johnson announced its fiscal second-quarter sales and earnings results ending June 28, 2026. The company filed this disclosure under Item 2.02 of its current report, which addresses results of operations and financial condition. The filing was authorized and signed by Robert J. Decker, Jr., Controller and Principal Accounting Officer.
The filing attaches the press release as Exhibit 99.1 and includes Exhibit 99.2, which contains unaudited comparative supplementary sales data and a condensed consolidated statement of earnings for both the quarter and the six-month period. Specific revenue figures, earnings per share, and segment results are not summarized within the report’s main text but are available in the referenced exhibits.
Six-Month Financial Comparisons Accompany Quarterly Data
Alongside the quarterly figures, Johnson & Johnson provided unaudited supplementary sales data for the first half of fiscal 2026. This information, part of Exhibit 99.2, presents a condensed consolidated earnings statement and sales data for the six months ending June 28, 2026, offering a broader perspective on the company’s financial performance through midyear.
The filing does not detail line-item financial metrics or segment breakdowns within the main narrative, directing readers to the exhibits for comprehensive data.
Details on Johnson & Johnson’s NYSE-Listed Common Stock
The report confirms Johnson & Johnson’s common stock has a par value of $1.00 per share and is listed on the New York Stock Exchange under the symbol JNJ. The company is incorporated in New Jersey with principal offices at One Johnson & Johnson Plaza, New Brunswick, New Jersey 08933. The IRS Employer Identification Number is 22-1024240.
Johnson & Johnson is classified as a non-emerging growth company, indicating it adheres to standard reporting requirements without extended transition periods for new accounting standards.
Ten Series of NYSE-Listed Notes with Maturities from 2028 to 2055
The filing lists ten separate series of Johnson & Johnson notes registered under Section 12(b) of the Securities Exchange Act and traded on the NYSE. Coupon rates range from 1.150% to 3.700%, with maturities spanning November 2028 through February 2055. Each note series carries a unique NYSE trading symbol.
The listed note series include: 1.150% Notes Due November 2028 (JNJ28); 2.700% Notes Due February 2029 (JNJ29B); 3.200% Notes Due June 2032 (JNJ32); 3.050% Notes Due February 2033 (JNJ33B); 1.650% Notes Due May 2035 (JNJ35); 3.350% Notes Due June 2036 (JNJ36A); 3.350% Notes Due February 2037 (JNJ37B); 3.550% Notes Due June 2044 (JNJ44); 3.600% Notes Due February 2045 (JNJ45); and 3.700% Notes Due February 2055 (JNJ55). All are confirmed as NYSE-listed in the disclosure.
Long-Term Debt Profile Spanning Nearly Three Decades
The maturity dates of Johnson & Johnson’s listed notes demonstrate a long-duration debt structure, ranging from the earliest maturity in November 2028 to the longest in February 2055, covering approximately 29 years. Coupon rates vary accordingly, from 1.150% on the 2028 notes to 3.700% on the 2055 notes.
The filing does not disclose outstanding principal amounts or aggregate long-term debt figures within the report.
Report Signed by Controller and Principal Accounting Officer Robert J. Decker, Jr.
The current report was signed on July 15, 2026, by Robert J. Decker, Jr., confirming the disclosure’s authorization on behalf of Johnson & Johnson. The filing does not include signatures from the CEO or CFO for this report.
The report indicates no check marks under written communications or solicitation provisions, confirming it is a routine earnings-related current report without alternative filing obligations.
Disclosure Filed Under Item 2.02 - Financial Results
This filing complies with Item 2.02 requirements for reporting material financial results. Johnson & Johnson attached the July 15, 2026, press release as Exhibit 99.1.
Item 9.01 lists three exhibits: Exhibit 99.1 (the press release), Exhibit 99.2 (unaudited supplementary sales data and condensed earnings statements), and Exhibit 104 (the Inline XBRL cover page). Full audited financial statements are not included in this current report.
Corporate and Registrant Information for Johnson & Johnson
Johnson & Johnson is incorporated in New Jersey, holding Commission File Number 1-3215 and CIK 0000200406. The company operates globally across pharmaceuticals, medical technology, and healthcare sectors. Its principal executive office is located at One Johnson & Johnson Plaza, New Brunswick, New Jersey 08933, with a contact phone number of 732-524-0400.
Exhibit 99.2 Offers Detailed Unaudited Sales Data for Q2 and H1 2026
Exhibit 99.2 provides unaudited comparative supplementary sales data and a condensed consolidated earnings statement for both the second quarter and the six-month period ending June 28, 2026. This supplementary data enables period-over-period comparisons across product lines and geographies, although the filing does not include detailed line-item breakdowns in the main report.
The unaudited status aligns with standard interim reporting practices prior to year-end audit completion.
Market Impact and Share Price Reaction Not Disclosed
The filing does not comment on any immediate market or share price reaction following the earnings announcement. Any stock price movement would be reflected in subsequent trading on the NYSE where JNJ is listed.
Johnson & Johnson remains a non-emerging growth company subject to full reporting standards. No updated financial guidance or forward-looking statements were included in this filing.
